Get the Stockscreener App
10.92
6.39%
-0.7357
Trevi Therapeutics Inc stock is traded at $10.92, with a volume of 811.81K.
It is down -6.39% in the last 24 hours and up +10.47% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$11.66
Open:
$11.74
24h Volume:
811.81K
Relative Volume:
0.39
Market Cap:
$1.33B
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-37.67
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
+3.95%
1M Performance:
+10.47%
6M Performance:
+56.15%
1Y Performance:
+262.62%
1-Day Range:
$10.71
$11.83
1-Week Range:
$10.30
$11.83
52-Week Range:
$2.36
$11.83
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
10.93 | 1.42B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.62 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.93 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.49 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.27 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.13 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Initiated | Morgan Stanley | Overweight |
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Should I hold or sell Trevi Therapeutics Inc. stock in 2025Weekly Trade Report & Technical Confirmation Trade Alerts - newser.com
What MACD signals say about Trevi Therapeutics Inc.Quarterly Investment Review & Intraday High Probability Alerts - newser.com
Will Trevi Therapeutics Inc. stock continue upward momentumJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com
Does Trevi Therapeutics Inc. show high probability of reboundWeekly Trade Report & Precise Swing Trade Entry Alerts - newser.com
Can Trevi Therapeutics Inc. stock reach $100 price targetWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com
What high frequency data says about Trevi Therapeutics Inc.Weekly Investment Recap & Free Growth Oriented Trading Recommendations - newser.com
Analyzing drawdowns of Trevi Therapeutics Inc. with statistical tools2025 Top Decliners & Daily Entry Point Alerts - newser.com
Using Bollinger Bands to evaluate Trevi Therapeutics Inc.July 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - newser.com
Is now a turning point for Trevi Therapeutics Inc.Quarterly Profit Report & Weekly Watchlist for Consistent Profits - newser.com
Technical signs of recovery in Trevi Therapeutics Inc.2025 Analyst Calls & Fast Entry High Yield Stock Tips - newser.com
Trevi Therapeutics Stock Soars on Clinical Progress and Institutional Backing - AD HOC NEWS
Historical volatility pattern of Trevi Therapeutics Inc. visualizedJuly 2025 PreEarnings & Precise Buy Zone Identification - newser.com
Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighWhat's Next? - MarketBeat
Trevi Therapeutics stock hits all-time high at 11.11 USD By Investing.com - Investing.com India
Momentum divergence signals in Trevi Therapeutics Inc. chartJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Applying sector rotation models to Trevi Therapeutics Inc.2025 Historical Comparison & Accurate Intraday Trade Tips - newser.com
Trevi Therapeutics stock hits all-time high at 11.11 USD - Investing.com
Trevi Therapeutics (TRVI) Projected to Post Earnings on Wednesday - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):